Scott Minick is a serial entrepreneur and venture capital partner. He holds a B.A. with Honors from University of California, San Diego, an MBA from Northwestern University and completed postgraduate studies in Neurobiology at the Salk Institute. Prior to becoming CEO at StrongHolt, Mr. Minick served as Managing Director of ARCH Venture Partners and Executive Chairman of Aira. He also served as President and CEO of BIND Therapeutics, acquired by Pfizer, President and COO of SEQUUS Pharmaceuticals, acquired by ALZA (and subsequently JNJ), and has served as board member for multiple Life Science companies including, Chiasma (NASDAQ: CHMA), BIND (NASDAQ: BIND), Xenoport (NASDAQ: XENO), along with numerous privately held companies. He formerly held positions in executive management at Baxter and Eli Lilly.